

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)**

**Thursday, March 9, 2017**

**145th Meeting of the Vaccines and Related Biological Products Advisory Committee  
NIH Conference Center  
5635 Fishers Lane, Rockville, MD 20850**

**Live Webcast: <https://videocast.nih.gov>**

**FINAL AGENDA**

| <b>Time</b> | <b>Presentation/ Presenter</b>   |
|-------------|--|
| 8:30 A.M.   | <p><b>Call to Order and Opening Remarks</b><br/><b>Introduction of Committee</b><br/>Kathryn Edwards, M.D. Chair, VRBPAC</p> <p><b>Conflict of Interest Statement</b><br/>Prabhakara Atreya, Ph.D.<br/>Acting Designated Federal Officer<br/>VRBPAC, FDA</p>   |
|             | <b>Topic: Strain Selection for the Influenza Virus Vaccines for the 2017-2018 Influenza Season</b>   |
| 8:45 a.m.   | <p><b>Introduction</b><br/>Anissa Cheung, M.Sc. Regulatory Coordinator Division of Viral Products<br/>Office of Vaccines Research and Review<br/>CBER/FDA</p>  |
| 8:55 a.m.   | <p><b>U.S. Surveillance</b><br/>Lisa Grohskopf, M.D., M.P.H. CAPT. USPHS<br/>Associate Chief for Policy &amp; Liaison<br/>Activities, Epidemiology &amp; Prevention Branch, Influenza Division<br/>Centers for Disease Control and Prevention</p>  |
| 9:20 a.m.   | <p><b>World Surveillance/Virus Characterization</b><br/>Jacqueline Katz, Ph.D.<br/>Deputy Director, Influenza Division and<br/>Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of<br/>Influenza National Center for Immunization and Respiratory Diseases<br/>Centers for Disease Control and Prevention</p> |
| 10:30 a.m.  | <b>BREAK</b>   |
| 10:45 a.m.  | <p><b>DoD Vaccine Effectiveness Report</b><br/>Michael Cooper, Ph.D. CAPT, USPHS Respiratory Infection Surveillance<br/>Global Emerging Infections Section, Armed Forces Health Surveillance Branch<br/>Silver Spring, MD</p>  |
| 11:10 a.m.  | <p><b>Candidate Vaccine Strains &amp; Potency Reagents</b><br/>Manju Joshi, Ph.D. Lead Biologist<br/>Division of Biological Standards &amp; Quality<br/>Office of Compliance and Biologics Quality<br/>CBER/FDA</p>  |

| <b>Time</b> | <b>Presentation/ Presenter</b>   |
|-------------|--|
| 11:30 a.m.  | <b>Comments from Manufacturers</b><br>Beverly Taylor, Ph.D.<br>Head of Influenza Scientific Affairs and Pandemic Readiness<br>Seqirus Vaccines Limited<br>United Kingdom |
| 11:55 a.m.  | <b>LUNCH</b>   |
| 12:50 p.m.  | <b>Open Public Hearing</b>   |
| 1:50 p.m.   | <b>Committee Discussion, Voting, and Recommendations</b>   |
| 3:00 p.m.   | <b>Adjournment</b>   |